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Abstract
Background and aims
Many countries lack resources to identify patients at risk of developing Type 2 diabetes mel-
litus (diabetes). We aimed to develop and validate a diabetes risk score based on easily
accessible clinical data.
Methods
Prospective study including 5277 participants (55.0% women, 51.8±10.5 years) free of dia-
betes at baseline. Comparison with two other published diabetes risk scores (Balkau and
Kahn clinical, respectively 5 and 8 variables) and validation on three cohorts (Europe, Iran
and Mexico) was performed.
Results
After a mean follow-up of 10.9 years, 405 participants (7.7%) developed diabetes. Our
score was based on age, gender, waist circumference, diabetes family history, hypertension
and physical activity. The area under the curve (AUC) was 0.772 for our score, vs. 0.748
(p<0.001) and 0.774 (p = 0.668) for the other two. Using a 13-point threshold, sensitivity,
specificity, positive and negative predictive values (95% CI) of our score were 60.5 (55.5–
65.3), 77.1 (75.8–78.2), 18.0 (16.0–20.1) and 95.9 (95.2–96.5) percent, respectively. Our
score performed equally well or better than the other two in the Iranian [AUC 0.542 vs. 0.564
(p = 0.476) and 0.513 (p = 0.300)] and Mexican [AUC 0.791 vs. 0.672 (p<0.001) and 0.778
(p = 0.575)] cohorts. In the European cohort, it performed similarly to the Balkau score but
worse than the Kahn clinical [AUC 0.788 vs. 0.793 (p = 0.091) and 0.816 (p<0.001)].
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Diagnostic capacity of our score was better than the Balkau score and comparable to the
Kahn clinical one.
Conclusion
Our clinically-based score shows encouraging results compared to other scores and can be
used in populations with differing diabetes prevalence.
Introduction
Diabetes mellitus is an important cause of morbidity, mortality and costs [1]. According to the
NCD Risk factor Collaboration, the number of adults with diabetes worldwide increased from
108 million in 1980 to 422 million in 2014 [1]. Most new cases of diabetes will occur in low
and middle-income countries, mainly due to the escalating prevalence of adiposity, rapidly
changing dietary and physical activity behaviors, and lack of or late identification of people at
risk of diabetes. Indeed, in low-income countries such as India, the prevalence of diabetes
could be as high as 19.9% [2].
Early identification of people at risk of diabetes is paramount for adequate prevention by
changes in lifestyle, and, if necessary, complemented by treatment. Thus, it is important to
have an easily obtainable, inexpensive and reliable diabetes risk score. A review conducted in
2011 [3] identified as many as 145 diabetes risk models or scores and suggested that this num-
ber increases monthly. Among the 94 risk prediction models studied, 40 were based on biolog-
ical variables [3]. Inclusion of biological variables in diabetes risk scores has a dual effect: it
slightly improves the scores’ performances [4], but it also increases costs (staff and laboratory)
and time (blood sampling, waiting for results). In a previous study, we have shown that the use
of a diabetes risk score including biological variables cost an additional US $ 12.02 per patient
compared to a score based on clinical data only [5]. Hence, in countries most affected by the
current diabetes epidemic, the use of diabetes risk scores including biological variables may
not be possible due to financial or laboratory constraints.
Thus, our first aim was to derive a diabetes risk score based solely on easily obtainable clini-
cal data, and to validate it in a similar European population by comparing it with existing clini-
cal scores. Our second aim was to examine the validity of our score regarding clinical utility
and application on populations with different diabetes and obesity prevalence, and lesser eco-
nomical means, using two different cohorts from Iran and Mexico.
Materials and methods
Sampling procedure
The CoLaus/PsyCoLaus study is a prospective population-based study intended to evaluate the
prevalence and determinants of cardiovascular disease in the population of Lausanne, Switzer-
land. Details of the sampling procedure have been previously documented [6] and can be
accessed online (www.colaus-psycolaus.ch). The source population was all adults aged 35 to 75
years in the Lausanne population register. A simple non-stratified random sample of 35% of
the source population was drawn and an invitation letter sent. If the latter went unanswered, a
second letter was sent and, if unanswered, several phone calls were performed. Recruitment
began in June 2003 and ended in May 2006, enrolling 6733 participants who underwent an
interview, a physical exam, and a blood analysis. The first follow-up was performed between
April 2009 and September 2012, a mean of 5.6 years after the collection of baseline data. The
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second follow-up was performed between May 2014 and July 2016, a mean of 10.9 years after
the collection of baseline data.
Clinical and biological data
All participants were examined in the morning after a fast of at least 8 hours. They were probed
about their personal and family history of cardiovascular disease and cardiovascular risk fac-
tors. All prescribed and over-the-counter medicines were collected via questionnaire. Smoking
status was categorized as never, former (irrespective of the time since quitting) and current
(irrespective of the amount smoked). Educational level was categorized as low (primary), mid-
dle (apprenticeship), upper middle (high school), and high (university) for highest completed
level of education. Physical activity was defined by exercising at least twice per week for at least
20 minutes per session.
Body weight and height were measured with participants barefoot and in light indoor
clothes. Body weight was measured in kilograms to the nearest 100 g using a Seca scale (Ham-
burg, Germany). Height was measured to the nearest 5 mm using a Seca (Hamburg, Germany)
height gauge. Waist circumference was measured mid-way between the lowest rib and the iliac
crest using a non-stretchable tape and the mean of two measurements was taken. Blood pres-
sure (BP) was measured using an Omron HEM-907 automated oscillometric sphygmoma-
nometer after at least a 10-minute rest in a seated position, and the mean of the last two
measurements was used. Hypertension was defined by a SBP�130 mm Hg or a DBP�85 mm
Hg or presence of antihypertensive drug treatment. Based on the review by Noble et al., the
130/85 mmHg threshold was preferred to the 140/90 mmHg one. High resting heart rate was
defined by� 68 beats per minute in men and�70 beats per minute in women.
Venous blood samples (50 mL) were drawn in the fasting state. Most biological assays were
performed at the clinical laboratory of the Lausanne university hospital within 2 hours of
blood collection. Glucose was assessed by glucose dehydrogenase with a maximum inter- and
intra-assay CV of 2.1% and 1.0%, respectively; glycated hemoglobin (HbA1c) was assessed by
HPLC (Bio-Rad, D-10TM, Reinach, Switzerland); total cholesterol by CHOD-PAP (1.6%-
1.7%); HDL-cholesterol by CHOD-PAP + PEG + cyclodextrin (3.6%-0.9%); triglycerides by
GPO-PAP (2.9%-1.5%).
Incident diabetes mellitus
Two definitions of incident diabetes were used: 1) fasting glucose level�7 mmol/L and/or
presence of an oral antidiabetic or insulin treatment, and 2) an HbA1c�6.5% (48 mmol/mol)
and/or presence of an oral antidiabetic or insulin treatment. As HbA1c was assessed only in
the last follow-up, analyses were restricted to participants who attended the second follow-up.
Other clinically-based diabetes mellitus risk scores for comparison
Two diabetes risk scores based solely on clinical data were considered: the score by Balkau
et al. [7] derived from a French population and the clinical score by Kahn et al. [8] derived
from a United States population (S1 Table). The score by Balkau et al. is based on five variables,
and the score by Kahn et al. is based on eight variables. Both scores had been tested previously
in our cohort [5].
Inclusion and exclusion criteria
The original inclusion criteria into the CoLaus/PsyCoLaus Study were: 1) written informed
consent; 2) willingness to take part in the examination and to provide blood samples; 3) French
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language ability. For this study, the following exclusion criteria were applied: 1) participants
with type 1 and 2 diabetes at baseline; 2) no follow-up and 3) missing data for calculation of
scores.
Statistical analysis
Statistical analyses were conducted using Stata version 15.1 for Windows (Stata Corp, College
Station, Texas, USA). Participants characteristics were expressed as number (percentage) for
categorical variables or as mean±standard deviation for continuous variables. Between-group
comparisons were performed using chi-square or Fisher’s exact test for categorical variables
and student’s t-test for continuous variables. Multivariate analysis was conducted using logistic
regression; to facilitate future scoring, all continuous variables (i.e. age, BMI, waist. . .) were
categorized. Goodness of fit was assessed using the Hosmer-Lemeshow test with 10 categories;
model quality was estimated using the Akaike and the Bayesian information criteria (AIC and
BIC, respectively). For anthropometric data, models including only one of each parameter
were computed, and the parameter providing the highest percentage of variance explained
(pseudo-R2) was selected. The diabetes risk score was created taking into account the contribu-
tion of each variable significantly associated with diabetes in the logistic model. The score was
built as the sum of assigned points, defined as the OR rounded to the nearest integer, as per-
formed in another setting [9]. The best threshold to define a high risk of diabetes was based
after visual examination of the graphs displaying the values of sensitivity, specificity, positive
and negative predictive values according to the score values, priority being given to a high
specificity and a high negative predictive value.
The diagnostic capacity of the different scores was assessed by the AUC [area under the
ROC (receiver operating characteristic) curve] and corresponding 95% confidence intervals
(CI). Comparisons between scores were performed using the roccomp command of Stata.
Sensitivity, specificity, positive and negative predictive values and their corresponding 95%
CIs were computed using incident diabetes (definition 1) as gold standard. The number
needed to screen (NNS) to detect one case of diabetes was computed as the number of detected
diabetes cases (i.e. true positives) divided by the total number of participants screened. Statisti-
cal significance was assessed for a two-sided test with p<0.05.
As women with gestational diabetes are at higher risk of developing diabetes type 2, a last
sensitivity analysis was performed after excluding women with personal history of gestational
diabetes.
External validation cohorts
The performance of our diabetes risk score relative to two other clinically based diabetes risk
scores was assessed in three cohorts. The European cohort included data from four countries
(France, Germany, Netherlands and UK) of the EPIC-Europe cohort study [10]; these four
countries were included because all relevant variables were available. Incident diabetes was
defined using multiple sources of evidence including self-report, linkage to primary-care regis-
ters, secondary-care registers, medication use, hospital admissions and mortality data [11].
Tlalpan 2020 is a cohort of participating Mexico City residents recruited through promotional
strategies in Mexico City, Mexico [12]; incident diabetes was defined as a fasting plasma glu-
cose�7 mmol/L. The Shahedieh cohort study included data from a population-based survey
in the province of Yazd, Iran [13] where incident diabetes was defined as a fasting plasma glu-
cose�7 mmol/L.
We report our results according to the TRIPOD (transparent reporting of a multivariable
prediction model for individual prognosis or diagnosis) statement [14].
Validation of a diabetic risk score
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Ethical considerations
The institutional Ethics Committee of the University of Lausanne, which afterwards became
the Ethics Commission of Canton Vaud (http://www.cer-vd.ch) approved the baseline
CoLaus/PsyCoLaus study (reference 16/03, decisions of January 13 and February 10, 2003);
the approval was renewed for the first (reference 33/09, decision of February 23, 2009) and the
second (reference 26/14, decision of March 11, 2014) follow-up.
The institutional review boards for the various EPIC cohorts are the following: United
Kingdom: Norfolk Research Ethics Committee; France: CNIL (Commission nationale de
l’informatique et des liberte´s); Netherlands: Bilthoven Medical Ethical Committee of TNO
Nutrition and Food Research; Institutional Review Board of the University Medical Center
Utrecht; Germany: Ethical committee of the State of Brandenburg, Germany.
The Institutional Bioethics Committee of the INCICh, within the ethical framework of the
seventh revision of the Declaration of Helsinki and the Regulations of the General Health Law
in Matters of Research for Health of Mexico, approved the Tlalpan 2020 study of the incidence
of systemic hypertension in a cohort of Mexico City residents and the written consent formats,
under number 13–802 on February 19, 2013; since then, protocol and writer consent had been
renewed yearly (September 23, 2014; November 17, 2015; September 13, 2016; May 16, 2017;
September 26, 2018).
The institutional Ethics Committee of Digestive Disease Research Institute at Tehran Uni-
versity of Medical Sciences (http://ethics.research.ac.ir/) approved the baseline Shahedieh
cohort study (reference: IR.TUMS.DDRI.Rec.1396.1); the approval was renewed for the first
follow-up (reference IR.SSU. Rec.1397.135, decision of January 22, 2019).
All studies were performed in agreement with the Helsinki declaration and its former
amendments. All participants gave their signed informed consent before entering the studies.
Results
Characteristics of participants
Of the initial 6733 patients, 21.6% were excluded, leaving 5277 participants (78.4%) for analy-
sis. The reasons for exclusion are summarized in Fig 1 and the comparison between excluded
and included participants is provided in S2 Table. Excluded participants were older, with
higher BMI and waist circumference. They were also more frequently men, sedentary, of lower
educational level, former or current smokers, with higher alcohol consumption, with a per-
sonal history of CVD, hypertension and lipid lowering drugs, and with a parental or family
history of diabetes.
Incidence of diabetes and score components
Between baseline and second follow-up, 405 participants (7.7%) developed diabetes as based
on fasting plasma glucose. The bivariate comparison of 19 candidate variables between partici-
pants who developed and who remained free of diabetes is summarized in Table 1. In both
genders, participants who developed diabetes were older, with higher BMI, waist, waist to
height and waist to hip ratios. Participants who developed diabetes were also of lower educa-
tional level, had a higher frequency of hypertension, lipid lowering drugs, personal history of
CVD and family history of diabetes, and a lower frequency of leisure-time physical activity
(Table 1).
The variables significantly associated with incident diabetes on bivariate analysis were
introduced in a multivariable logistic regression model. Based on the results of the logistic
regression and the percentage of variance explained, the following variables were selected for
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the diabetes risk score: gender, age, waist circumference, hypertension, family history of diabe-
tes, and physical activity. The scoring system is provided in Table 2. First, we developed a sepa-
rate scoring system for men and women. Nevertheless, as we wanted to keep the score as
simple as possible, we developed a final scoring, applicable to either sex. The odd ratios
enabling the scores are provided in S3 Table. Waist was the most important determinant of
incident diabetes, while no increasing effect of age categories were found. The threshold of 13
points provided the best combination of sensitivity and specificity.
The comparison between our scoring system and the other diabetes risk scores for the
CoLaus/PsyCoLaus study is provided in Table 3. Based on the AUC; our score performed bet-
ter than the score by Balkau et al., while no differences were found with the score by Kahn
et al. Similar findings were observed when the analysis was split by gender. The results of the
diagnostic capacity of the different scores, overall and stratified by gender are provided in
Table 4. Compared to the score by Balkau et al., our score had a higher sensitivity and negative
predictive value, but a lower specificity. Compared to the score by Kahn et al., our score had
comparable diagnostic capacities, and a slightly better specificity (Table 4). Similar findings
were observed when the analysis was split by gender (Table 4). The goodness of fit and infor-
mation criteria are provided in S4 Table.
Fig 1. Flowchart of the participants of the CoLaus/PsyCoLaus study.
https://doi.org/10.1371/journal.pone.0218933.g001
Validation of a diabetic risk score
PLOS ONE | https://doi.org/10.1371/journal.pone.0218933 October 9, 2019 6 / 16
Table 1. Bivariate analysis of the factors associated with incident diabetes mellitus, stratified by gender. CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003–
2017.
Women Men
Non-diabetic Diabetic P-value Non-diabetic Diabetic P-value
Sample size 2755 149 2117 256
Age (years) 52.2 ± 10.5 57.5 ± 9 <0.001 50.5 ± 10.3 54.9 ± 10.1 <0.001
Anthropometry
Height (cm) 163 ± 7 162 ± 6 0.016 175 ± 7 174 ± 7 0.011
Weight (kg) 64.9 ± 11.7 75.9 ± 13.6 <0.001 79.7 ± 12 86.3 ± 13.2 <0.001
Body mass index (kg/cm2) 24.5 ± 4.3 29.1 ± 5.0 <0.001 25.9 ± 3.5 28.4 ± 3.9 <0.001
Waist circumference (cm) 81.6 ± 11.1 95.0 ± 12.5 <0.001 93.5 ± 10 100.9 ± 10.3 <0.001
Waist to height ratio 50.2 ± 7.2 58.9 ± 8.0 <0.001 53.4 ± 5.8 58.0 ± 6.0 <0.001
Waist to hip ratio 0.82 ± 0.07 0.88 ± 0.06 <0.001 0.92 ± 0.06 0.95 ± 0.05 <0.001
Educational level 0.001 <0.001
University 494 (17.9) 13 (8.7) 573 (27.1) 41 (16.0)
High school 730 (26.5) 33 (22.2) 523 (24.7) 55 (21.5)
Apprenticeship 969 (35.2) 57 (38.3) 735 (34.7) 106 (41.4)
Mandatory education 562 (20.4) 46 (30.9) 286 (13.5) 54 (21.1)
Smoking status 0.434 0.024
Never 1292 (46.9) 62 (41.6) 758 (35.8) 70 (27.3)
Former 785 (28.5) 48 (32.2) 779 (36.8) 103 (40.2)
Current 678 (24.6) 39 (26.2) 580 (27.4) 83 (32.4)
BP� 130/85 mm Hg 963 (35.0) 92 (61.7) <0.001 1026 (48.5) 172 (67.2) <0.001
Hypertension † 1063 (38.6) 101 (67.8) <0.001 1100 (52.0) 193 (75.4) <0.001
High resting heart rate ‡ 1155 (41.9) 62 (41.6) 0.940 892 (42.1) 127 (49.6) 0.022
Lipid lowering drugs 216 (7.8) 26 (17.5) <0.001 222 (10.5) 44 (17.2) 0.001
Alcohol�35 drinks/week 9 (0.3) 0 (0) 1.00 § 60 (2.8) 14 (5.5) 0.022
Caffeinated drinks (units/day) 0.644 0.197
None 178 (6.5) 12 (8.1) 128 (6.1) 13 (5.1)
1–3 1819 (66.0) 94 (63.1) 1350 (63.8) 170 (66.4)
4–6 654 (23.7) 35 (23.5) 533 (25.2) 54 (21.1)
>6 104 (3.8) 8 (5.4) 106 (5.0) 19 (7.4)
Leisure-time PA�2/week 1599 (58.0) 67 (45.0) 0.002 1162 (54.9) 114 (44.5) 0.002
Personal history of CVD 116 (4.2) 13 (8.7) 0.009 110 (5.2) 27 (10.6) 0.001
Parental history of diabetes <0.001 § 0.015 §
No 2262 (82.1) 99 (66.4) 1777 (83.9) 195 (76.2)
Mother only 262 (9.5) 26 (17.5) 164 (7.8) 31 (12.1)
Father only 210 (7.6) 21 (14.1) 165 (7.8) 28 (10.9)
Both 21 (0.8) 3 (2.0) 11 (0.5) 2 (0.8)
Family history of diabetes
Type 1+2 612 (22.2) 65 (43.6) <0.001 402 (19.0) 72 (28.1) 0.001
Type 2 586 (21.3) 64 (43.0) <0.001 390 (18.4) 71 (27.7) <0.001
BP, blood pressure; CVD, cardiovascular disease; PA, physical activity.
† defined by SBP�130 mm Hg or DBP� 85 mm Hg or presence of antihypertensive drug treatment;
‡, defined by�68 beats per minute in men and�70 beats per minute in women.
Results are expressed as mean ± standard deviation or as number of participants (%). Between-group comparisons performed using student’s t-test for continuous
variables and chi-square or Fisher’s exact test (§) for categorical variables.
https://doi.org/10.1371/journal.pone.0218933.t001
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Sensitivity analysis
A sensitivity analysis was performed using diabetes based on HbA1c. Of the 4297 participants
devoid of diabetes at baseline and who came to the second follow-up, 255 (5.9%) developed
diabetes based on HbA1c. The results are summarized in S5 and S6 Tables. Our score showed
a higher AUC than the score by Balkau et al., while no differences were found with the score
by Kahn et al. (S5 Table), and similar findings were observed for the diagnostic capacity (S6
Table).
Sensitivity analysis after excluding 30 women with personal history of gestational diabetes
led to similar findings (S7 and S8 Tables).
External validation cohorts
The characteristics of the different external validation cohorts are summarized in S9–S11
Tables. The results of our diabetes risk score compared with the other two clinically based dia-
betes risk scores for each of the three cohorts (European, Tlalpan 2020 and Shahedieh) are
summarized in S12 and S13 Tables. Based on the AUC, our score performed better than both
scores in the Tlalpan 2020 cohort, better than Kahn et al. on the Shahedieh cohort but per-
formed less well in the European cohort (S12 Table). Our score had a better sensitivity and
negative predictive value and a lower specificity and positive predictive value than the score of
Balkau et al; the diagnostic capacity was similar to the score by Kahn et al. (S13 Table).
Discussion
Our score provides an easy way of screening people at risk of developing diabetes; further, and
contrary to many other scores [3], it was replicated in other cohorts in Europe and in two
developing countries.
Table 2. Clinical score for predicting type 2 diabetes mellitus risk.
Men Women Final scoring
Male gender - - 2
Age group (years)
[45–54] 2 3 2
[55–64] 2 3 2
[65–75] 2 3 2
Waist (cm)
70–79 W, 80–89 M 3 2 2
80–89 W, 90–99 M 6 6 6
90–99 W, 100–109 M 12 12 12
100–109 W, 110–120 M 14 22 18
110+ W, 120+ M 32 31 32
Family history of diabetes § 2 2 2
Physical inactivity ǂ 1 1 1
Hypertension † 2 2 2
M, men; W, women.
§: father, mother or siblings;
ǂ: less than twice 20 minutes leisure physical activity per week;
†: systolic blood pressure� 130 mm Hg and/or diastolic blood pressure� 85 mmHg and/or antihypertensive drug
treatment.
https://doi.org/10.1371/journal.pone.0218933.t002
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Variables in the model
A previous systematic review identified 29 clinical (i.e. non biological) variables associated
with incident diabetes [3]. In this study, we were able to assess the predictive capacity of 19 of
them, and six were selected for the final model.
Table 3. Areas under the receiver operating characteristic (ROC) curves and incidence of diabetes per quintile of diabetes risk estimation score, overall and strati-
fied by gender, CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003–2017.
AUC (95% CI) P-value § First Second Third Fourth Fifth
All participants
CoLaus/PsyCoLaus 0.772 (0.750–0.794) 1.0 3.0 6.0 10.8 20.2
Balkau 0.748 (0.726–0.770) <0.001 1.0 5.0 9.1 NA 19.7
Kahn clinic 0.774 (0.753–0.796) 0.668 0.7 2.5 5.4 10.7 20.0
Women (n = 2904)
CoLaus/PsyCoLaus 0.806 (0.772–0.840) 0.8 2.4 4.3 7.2 18.4
Balkau 0.788 (0.753–0.822) 0.024 0.8 2.8 6.4 NA 16.9
Kahn clinic 0.807 (0.774–0.839) 0.948 0.4 1.5 4.6 7.6 17.8
Men (n = 2373)
CoLaus/PsyCoLaus 0.719 (0.688–0.751) 1.8 3.9 7.3 13.6 21.5
Balkau 0.700 (0.670–0.730) 0.065 1.6 7.8 11.5 NA 22.2
Kahn clinic 0.728 (0.698–0.758) 0.283 1.5 4.2 6.4 13.9 21.4
Results are expressed as area under the curve and (95% confidence interval), and as percentage of participants developing diabetes during the 10.9 year follow-up.
Diabetes was defined as fasting glucose level�7 mmol/L and/or presence of an oral antidiabetic or insulin treatment
https://doi.org/10.1371/journal.pone.0218933.t003
Table 4. Diagnostic capacity of the different scores, overall and stratified by gender, CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003–2017.
Threshold Sensitivity Specificity Positive PV Negative PV N needed to screen
All participants
CoLaus/PsyCoLaus 13 60.5
(55.5–65.3)
77.1
(75.8–78.2)
18.0
(16.0–20.1)
95.9
(95.2–96.5)
22
Balkau 5 10.1
(7.4–13.5)
97.4
(96.9–97.8)
24.4
(18.1–31.6)
92.9
(92.1–93.6)
129
Kahn clinic 38 64.0
(59.1–68.6)
74.6
(73.4–75.8)
17.3
(15.4–19.3)
96.1
(95.5–96.7)
20
Women (n = 2904)
CoLaus/PsyCoLaus 13 66.4
(58.3–74.0)
79.8
(78.2–81.3)
15.1
(12.4–18.1)
97.8
(97.1–98.3)
29
Balkau 5 13.4
(8.4–20.0)
97.9
(97.3–98.4)
26.0
(16.6–37.2)
95.4
(94.6–96.2)
145
Kahn clinic 38 62.4
(54.1–70.2)
80.7
(79.1–82.1)
14.9
(12.2–17.9)
97.5
(96.8–98.1)
31
Men (n = 2373)
CoLaus/PsyCoLaus 13 57.0
(50.7–63.2)
73.5
(71.6–75.4)
20.7
(17.7–23.8)
93.4
(92.1–94.5)
16
Balkau 5 8.2
(5.2–12.3)
96.7
(95.8–97.4)
23.1
(14.9–33.1)
89.7
(88.4–90.9)
113
Kahn clinic 38 64.8
(58.7–70.7)
66.8
(64.7–68.8)
19.1
(16.5–21.9)
94.0
(92.7–95.2)
14
PV, predictive value; N, number. Results are expressed as value and (95% confidence interval). Number needed to screen to detect one true incident case of diabetes
mellitus was computed as number of participants screened/number of participants who developed diabetes and who scored positive
https://doi.org/10.1371/journal.pone.0218933.t004
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Age was included in the model, as it is in most risk assessment models [8, 15–17]. The risk
of diabetes increases with age [18], although in our model no such increase in risk was found.
A possible explanation is that other factors such as waist or physical inactivity also increase
with age [19, 20], thus cancelling the age-specific increase in diabetes risk.
Gender was also included in the model, as in other scores [7, 17]. Indeed, male sex is associ-
ated with a higher risk of diabetes independently of other risk factors [21].
Waist circumference was the obesity measure selected for our score, as it is also used in
many other scores [7, 8, 15, 16]. Waist circumference was by far the strongest variable in
our score, a finding in agreement with the literature, where abdominal obesity has been
found to be the strongest adiposity determinant of diabetes [22, 23]. Importantly, the sole
presence of a high waist circumference was enough to consider a subject as at high risk of
diabetes, suggesting that waist measurement could already provide important information
regarding the risk of diabetes, as it is the case for other populations such as in India [24], or
Brazil [25].
Hypertension was included in our score, as it was in many other diabetes risk scores [7, 8,
15–17]. Hypertension is known to be associated with development of diabetes [26–28]. For
our score, we defined hypertension as a SBP�130 mm Hg or DBP�85 mm Hg or the presence
of antihypertensive drug treatment, but different possible definitions (measured; anamnestic;
hypertension medication) have been used [7, 8, 15–17]. We chose to use measured hyperten-
sion in our score as this condition is also very prevalent in the general population [29] and is a
major risk factor for cardiovascular disease [30]. Hence, assessing risk of diabetes using our
score would also help to detect (and manage) hypertension.
Family history of diabetes is generally easy to obtain and was included in our score, as it is
in most scores [7, 8, 15, 17]. The presence of a positive family history underlines a genetic com-
ponent to diabetes but can also reflect the lifestyle or the environmental conditions people
were used to during their upbringing [31].
Lack of physical activity was included in the score, as it is also in some other scores. [15,
16]. Physical activity is hard to categorize using a standard procedure; indeed, in this study, it
was not possible to obtain a homogeneous definition for physical activity within all cohorts,
see S14 Table [32, 33]. Still, irrespective of this limitation, the results were quite similar
between cohorts. Hence, our results suggest that even a bold definition of physical activity may
suffice to predict the risk of diabetes. This should encourage people to be more active because
it underlines that even a small amount of physical activity is better than nothing [34].
Comparison with other scores
When using CoLaus/PsyCoLaus data, the AUC of our score performed better than the one by
Balkau et al. and similarly to Kahn clinic. Our score’s sensitivity was higher than Balkau’s and
similar to Kahn’s clinical score. Our specificity was inferior to Balkau’s but similar to Kahn’s
clinical score. The positive and negative predictive values were similar to Kahn’s. Although the
score by Balkau et al. showed the highest specificity among all cohorts, it led to a considerable
underestimation of the prevalence of subjects at risk. For instance, in Iran, the prevalence of
subjects at risk according to the score of Balkau et al. was considerably lower than the reported
prevalence of diabetes (11.37%) [35].
Overall, our results suggest that our score performs equally well or even better than existing
ones. Importantly, the number needed to screen was considerably lower than obtained using
the score by Balkau et al., and comparable to the score by Kahn et al. This has important conse-
quences for screening, as is suggests that, for a given number of people screened, a higher
number of people who will develop diabetes will be detected.
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Strengths and limitations
The main strength of our study is that the score was replicated on three cohorts from different
continents with contrasting diabetes prevalence [36] (S15 Table), a control seldom performed
for other scores [3]. Indeed, our score’s AUC in these cohorts is comparable or better than
Balkau et al.’s and Kahn et al.’s. Secondly, our score performs similarly to Kahn’s clinical score,
but with a smaller number of variables. Importantly, the previous review indicated that many
models and scores were not used because they required tests not routinely available or were
developed without a specific user in mind [3]. Our score overcomes those two limitations, as
it is based on easily accessible data, which could be collected by non-medical professionals.
Hence, it could be implemented worldwide with little effort. A third strength is that obesity
prevalence in women was different in each replication cohort, which reinforces our score. In
men, however, average waist circumference was very similar among the cohorts. Fourthly,
although part of the type 2 diabetes epidemic is due to environmental factors, our score is
important on a personal level. Indeed, if one calculates one’s diabetes score and it is elevated,
every individual can decide to act upon the three modifiable variables (hypertension, waist cir-
cumference and physical activity). Fifthly, the scoring system could be adapted to the charac-
teristics of the populations, by changing the threshold and/or the weights of its parameters, as
it has been done for cardiovascular risk scores [37]. Sixthly, the American Diabetes Assocation
(ADA) recommends testing all people, beginning at age 45 years.[38] The CoLaus/PsyColaus
sample included adults aged 35 to 75, which is within the recommended age frame. Finally,
our score includes 4 of the 9 criteria issued by the ADA recommendations for testing diabetes
or prediabetes in asymptomatic adults: overweight, hypertension, family history, physical inac-
tivity.[38] This shows the importance of these variables in the development of diabetes.
This study also has some limitations worth acknowledging. Firstly, participants excluded
from the analysis presented higher prevalence of several components of the diabetes risk score.
Hence, it is likely that the impact of some components might have been different, had those
participants been included in the analysis. Still, external validation of the analysis in other
cohorts led to similar findings. Secondly, the number of incident diabetes cases was relatively
low in the Shahedieh cohort, a finding likely due to a short follow-up time (1 year) and leading
to a lower statistical power. Hence, it would be of interest to replicate the analysis in the forth-
coming years with a larger number of incident diabetes cases. Thirdly, we were unable to vali-
date our score on a South-Eastern Asian country, where waist circumference is considered as a
major determinant of diabetes [39]. Still, given the importance of waist circumference in our
score, we hypothesize that it would perform relatively well in those countries, although an
external validation study in a South-Eastern Asian country is necessary to test this hypothesis,
especially in the genetically lean Asian men. Fourthly, physical activity was assessed differently
in each cohort (S14 Table). Assessing physical activity in a standardized manner is a difficult
task, and there is even lack of standardization when physical activity is measured using accel-
erometry [40]. Hence, we chose a very pragmatic solution, where each cohort would define
physical activity according to its own standards. We acknowledge that this procedure increases
variability between cohorts, but on the other hand it allows the use of our score by many other
cohorts. Fifthly, our score uses a fixed weight for all risk factors independently of the country
considered, while it has been suggested that the importance of conventional risk factors for
predicting diabetes varies between countries [41]. Indeed, levels of diabetes have been shown
to vary according to socio-economic status [42] and ethnicity [43]. However, in our study, nei-
ther ethnicity nor education came out as significant predictors for type 2 diabetes. Further,
waist circumference has been shown to be the best anthropometric predictor across all racial
and ethnic groups [44]. Moreover, due to its simple scoring system, our score allows the
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addition of other risk factors if the latter are considered as important in a given setting. Alter-
natively, it might be necessary to recalibrate our score according to country, as it has been sug-
gested for cardiovascular risk prediction [37]. Finally, as other scores, ours did not allow the
identification of all incident cases of diabetes. Still, it can be used with minimal clinical data,
and can thus be applied in settings with limited health resources where no screening for diabe-
tes risk is available.
Conclusion
Our clinically-based score shows comparable or even better results to other clinical scores and
can be used on different populations with contrasting diabetes prevalence.
Supporting information
S1 Table. Characteristics of the diabetes risk scores.
(DOCX)
S2 Table. Baseline characteristics of included and excluded participants, CoLaus/PsyCo-
Laus study, Lausanne, Switzerland.
(DOCX)
S3 Table. Results of the logistic regression using incident diabetes as dependent variable,
both genders, CoLaus/PsyCoLaus study.
(DOCX)
S4 Table. Goodness of fit and information criteria for each diabetes risk score, overall and
stratified by gender, CoLaus/PsyCoLaus study, Lausanne, Switzerland.
(DOCX)
S5 Table. Areas under the ROC and incidence of diabetes as defined by glycated haemoglo-
bin, per quintile of diabetes risk estimation score, overall and stratified by gender,
CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003–2017.
(DOCX)
S6 Table. Diagnostic capacity of the different scores, overall and stratified by gender, using
diabetes as defined by glycated haemoglobin, CoLaus/PsyCoLaus study, Lausanne, Swit-
zerland, 2003–2017.
(DOCX)
S7 Table. Areas under the receiver operating characteristic (ROC) curves and incidence of
diabetes per quintile of diabetes risk estimation score, women without history of gesta-
tional diabetes (n = 2874), CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003–2017.
(DOCX)
S8 Table. Diagnostic capacity of the different scores, women without history of gestational
diabetes (n = 2874), CoLaus/PsyCoLaus study, Lausanne, Switzerland, 2003–2017.
(DOCX)
S9 Table. Characteristics of the four countries (France, Germany, Netherlands and UK)
contributing data from the EPIC-Europe cohort study.
(DOCX)
S10 Table. Characteristics of the Tlalpan 2020 cohort, Mexico City, Mexico.
(DOCX)
Validation of a diabetic risk score
PLOS ONE | https://doi.org/10.1371/journal.pone.0218933 October 9, 2019 12 / 16
S11 Table. Characteristics of the Shahedieh cohort, Iran.
(DOCX)
S12 Table. Performance of the new score and of two other clinically based scores, in origi-
nal cohort (CoLaus/PsyCoLaus) and in the replication cohorts.
(DOCX)
S13 Table. Diagnostic capacity of the new score and of two other clinically based scores, in
original cohort (CoLaus/PsyCoLaus) and in the replication cohorts.
(DOCX)
S14 Table. Definitions of physical activity in the original and in the replication cohorts.
(DOCX)
S15 Table. Diabetes prevalence in percentage of adults in 2014 classified by country and
gender.
(DOCX)
Acknowledgments
The authors would like to thank the following EPIC-Europe centres for providing data for use
in the replication study: Norfolk, France, Bilthoven, Utrecht and Potsdam. They also thank
Tlalpan 2020 study team for their contribution and Janko Fabecic, student at the Faculty of
Biology and Medicine, University of Lausanne, Switzerland for sharing his bibliography on
diabetes scores.
Author Contributions
Conceptualization: Vanessa Kraege, Marie Me´an, Pedro Marques-Vidal.
Data curation: Stephen J. Sharp, Maite Vallejo, Oscar Infante, Mohammad Reza Mirjalili,
Fatemeh Ezoddini-Ardakani, Hassan Mozaffari-Khosravi, Mohammad Hasan Lotfi,
Masoud Mirzaei, Pedro Marques-Vidal.
Formal analysis: Stephen J. Sharp, Maite Vallejo, Oscar Infante, Mohammad Reza Mirjalili,
Fatemeh Ezoddini-Ardakani, Hassan Mozaffari-Khosravi, Mohammad Hasan Lotfi,
Masoud Mirzaei, Pedro Marques-Vidal.
Funding acquisition: Peter Vollenweider, Ge´rard Waeber.
Investigation: Vanessa Kraege, Peter Vollenweider, Stephen J. Sharp, Maite Vallejo, Oscar
Infante, Mohammad Reza Mirjalili, Fatemeh Ezoddini-Ardakani, Hassan Mozaffari-Khos-
ravi, Mohammad Hasan Lotfi, Masoud Mirzaei.
Methodology: Vanessa Kraege, Pedro Marques-Vidal.
Project administration: Vanessa Kraege.
Resources: Stephen J. Sharp, Maite Vallejo, Oscar Infante, Mohammad Reza Mirjalili, Fate-
meh Ezoddini-Ardakani, Hassan Mozaffari-Khosravi, Mohammad Hasan Lotfi, Masoud
Mirzaei.
Supervision: Marie Me´an.
Validation: Stephen J. Sharp, Maite Vallejo, Oscar Infante, Mohammad Reza Mirjalili, Fate-
meh Ezoddini-Ardakani, Hassan Mozaffari-Khosravi, Mohammad Hasan Lotfi, Masoud
Mirzaei.
Validation of a diabetic risk score
PLOS ONE | https://doi.org/10.1371/journal.pone.0218933 October 9, 2019 13 / 16
Visualization: Pedro Marques-Vidal.
Writing – original draft: Vanessa Kraege.
Writing – review & editing: Peter Vollenweider, Ge´rard Waeber, Stephen J. Sharp, Maite Val-
lejo, Oscar Infante, Mohammad Reza Mirjalili, Fatemeh Ezoddini-Ardakani, Hassan
Mozaffari-Khosravi, Mohammad Hasan Lotfi, Masoud Mirzaei, Marie Me´an.
References
1. N. C. D. Risk Factor Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751
population-based studies with 4.4 million participants. Lancet. 2016; 387(10027):1513–30. https://doi.
org/10.1016/S0140-6736(16)00618-8 PMID: 27061677
2. Geldsetzer P, Manne-Goehler J, Theilmann M, Davies JI, Awasthi A, Vollmer S, et al. Diabetes and
hypertension in India: a nationally representative study of 1.3 million adults. JAMA Intern Med. 2018;
178(3):363–72. https://doi.org/10.1001/jamainternmed.2017.8094 PMID: 29379964
3. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: sys-
tematic review. Bmj. 2011; 343:d7163. https://doi.org/10.1136/bmj.d7163 PMID: 22123912
4. Abbasi A, Peelen LM, Corpeleijn E, van der Schouw YT, Stolk RP, Spijkerman AM, et al. Prediction
models for risk of developing type 2 diabetes: systematic literature search and independent external val-
idation study. Bmj. 2012; 345:e5900. https://doi.org/10.1136/bmj.e5900 PMID: 22990994
5. Schmid R, Vollenweider P, Bastardot F, Waeber G, Marques-Vidal P. Validation of 7 type 2 diabetes
mellitus risk scores in a population-based cohort: CoLaus study. Arch Intern Med. 2012; 172(2):188–9.
https://doi.org/10.1001/archinte.172.2.188 PMID: 22271131
6. Firmann M, Mayor V, Vidal PM, Bochud M, Pecoud A, Hayoz D, et al. The CoLaus study: a population-
based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and
metabolic syndrome. BMC Cardiovasc Disord. 2008; 8:6. https://doi.org/10.1186/1471-2261-8-6 PMID:
18366642
7. Balkau B, Lange C, Fezeu L, Tichet J, de Lauzon-Guillain B, Czernichow S, et al. Predicting diabetes:
clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resis-
tance Syndrome (DESIR). Diabetes Care. 2008; 31(10):2056–61. https://doi.org/10.2337/dc08-0368
PMID: 18689695
8. Kahn HS, Cheng YJ, Thompson TJ, Imperatore G, Gregg EW. Two risk-scoring systems for predicting
incident diabetes mellitus in U.S. adults age 45 to 64 years. Ann Intern Med. 2009; 150(11):741–51.
https://doi.org/10.7326/0003-4819-150-11-200906020-00002 PMID: 19487709
9. Marti-Soler H, Hirotsu C, Marques-Vidal P, Vollenweider P, Waeber G, Preisig M, et al. The NoSAS
score for screening of sleep-disordered breathing: a derivation and validation study. Lancet Respir
Med. 2016; 4(9):742–8. https://doi.org/10.1016/S2213-2600(16)30075-3 PMID: 27321086
10. Bingham S, Riboli E. Diet and cancer—the European Prospective Investigation into Cancer and Nutri-
tion. Nat Rev Cancer. 2004; 4(3):206–15. https://doi.org/10.1038/nrc1298 PMID: 14993902
11. InterAct C, Langenberg C, Sharp S, Forouhi NG, Franks PW, Schulze MB, et al. Design and cohort
description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on
the incidence of type 2 diabetes in the EPIC Study. Diabetologia. 2011; 54(9):2272–82. https://doi.org/
10.1007/s00125-011-2182-9 PMID: 21717116
12. Colin-Ramirez E, Rivera-Mancia S, Infante-Vazquez O, Cartas-Rosado R, Vargas-Barron J, Madero M,
et al. Protocol for a prospective longitudinal study of risk factors for hypertension incidence in a Mexico
City population: the Tlalpan 2020 cohort. BMJ Open. 2017; 7(7):e016773. https://doi.org/10.1136/
bmjopen-2017-016773 PMID: 28760800
13. Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar AA, Hekmatdoost A, et al. Prospective Epi-
demiological Research Studies in Iran (the PERSIAN Cohort Study): Rationale, Objectives, and Design.
Am J Epidemiol. 2018; 187(4):647–55. https://doi.org/10.1093/aje/kwx314 PMID: 29145581
14. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction
model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Bmj. 2015; 350:g7594.
https://doi.org/10.1136/bmj.g7594 PMID: 25569120
15. Diabète Suisse. Test diabète Baden, Switzerland2017 https://www.diabetesschweiz.ch/fr/le-diabete/
test-diabete/.
16. Lindstro¨m J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabe-
tes Care. 2003; 26(3):725–31. https://doi.org/10.2337/diacare.26.3.725 PMID: 12610029
Validation of a diabetic risk score
PLOS ONE | https://doi.org/10.1371/journal.pone.0218933 October 9, 2019 14 / 16
17. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: towards earlier detec-
tion of type 2 diabetes in general practice. Diabetes Metab Res Rev. 2000; 16(3):164–71. PMID:
10867715
18. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000
and projections for 2030. Diabetes Care. 2004; 27(5):1047–53. https://doi.org/10.2337/diacare.27.5.
1047 PMID: 15111519
19. Stevens J, Katz EG, Huxley RR. Associations between gender, age and waist circumference. Eur J Clin
Nutr. 2010; 64(1):6–15. https://doi.org/10.1038/ejcn.2009.101 PMID: 19738633
20. Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among U.S. adults. Obes Res. 2003;
11(10):1223–31. https://doi.org/10.1038/oby.2003.168 PMID: 14569048
21. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Com-
plications of Type 2 Diabetes Mellitus. Endocr Rev. 2016; 37(3):278–316. https://doi.org/10.1210/er.
2015-1137 PMID: 27159875
22. Meisinger C, Doring A, Thorand B, Heier M, Lowel H. Body fat distribution and risk of type 2 diabetes in
the general population: are there differences between men and women? The MONICA/KORA Augs-
burg cohort study. Am J Clin Nutr. 2006; 84(3):483–9. https://doi.org/10.1093/ajcn/84.3.483 PMID:
16960160
23. Borne Y, Nilsson PM, Melander O, Hedblad B, Engstrom G. Multiple anthropometric measures in rela-
tion to incidence of diabetes: a Swedish population-based cohort study. Eur J Public Health. 2015; 25
(6):1100–5. https://doi.org/10.1093/eurpub/ckv044 PMID: 25817208
24. Prakash K, Chandran DS, Khadgawat R, Jaryal AK, Deepak KK. Waist Circumference Rather than
Body Mass Index is Better Indicator of Insulin Resistance in Type 2 Diabetes Mellitus in North Indian
Population. Indian J Physiol Pharmacol. 2016; 60(1):52–6. PMID: 29953194
25. Alvim Rde O, Mourao-Junior CA, de Oliveira CM, Krieger JE, Mill JG, Pereira AC. Body mass index,
waist circumference, body adiposity index, and risk for type 2 diabetes in two populations in Brazil: gen-
eral and Amerindian. PLoS One. 2014; 9(6):e100223. https://doi.org/10.1371/journal.pone.0100223
PMID: 24937307
26. Izzo R, de Simone G, Chinali M, Iaccarino G, Trimarco V, Rozza F, et al. Insufficient control of blood
pressure and incident diabetes. Diabetes Care. 2009; 32(5):845–50. https://doi.org/10.2337/dc08-1881
PMID: 19223610
27. Kim MJ, Lim NK, Choi SJ, Park HY. Hypertension is an independent risk factor for type 2 diabetes: the
Korean genome and epidemiology study. Hypertens Res. 2015; 38(11):783–9. https://doi.org/10.1038/
hr.2015.72 PMID: 26178151
28. Hayashi T, Tsumura K, Suematsu C, Endo G, Fujii S, Okada K. High normal blood pressure, hyperten-
sion, and the risk of type 2 diabetes in Japanese men. The Osaka Health Survey. Diabetes Care. 1999;
22(10):1683–7. https://doi.org/10.2337/diacare.22.10.1683 PMID: 10526735
29. Collaboration NCDRF. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of
1479 population-based measurement studies with 19.1 million participants. Lancet. 2017; 389
(10064):37–55. https://doi.org/10.1016/S0140-6736(16)31919-5 PMID: 27863813
30. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines
for the management of arterial hypertension. Eur Heart J. 2018; 39(33):3021–104. https://doi.org/10.
1093/eurheartj/ehy339 PMID: 30165516
31. Kolb H, Martin S. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes.
BMC Med. 2017; 15(1):131. https://doi.org/10.1186/s12916-017-0901-x PMID: 28720102
32. Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, et al. Validity and repeatability of
a simple index derived from the short physical activity questionnaire used in the European Prospective
Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr. 2003; 6(4):407–13. https://doi.
org/10.1079/PHN2002439 PMID: 12795830
33. Ipaq. https://sites.google.com/site/theipaq/scoring-protocol.
34. Hemmingsen B, Gimenez-Perez G, Mauricio D, Roque IFM, Metzendorf MI, Richter B. Diet, physical
activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in
people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;
12:CD003054. https://doi.org/10.1002/14651858.CD003054.pub4 PMID: 29205264
35. Esteghamati A, Etemad K, Koohpayehzadeh J, Abbasi M, Meysamie A, Noshad S, et al. Trends in the
prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005–2011. Dia-
betes Res Clin Pract. 2014; 103(2):319–27. https://doi.org/10.1016/j.diabres.2013.12.034 PMID:
24447808
36. [NCD Risk Factor Collaboration]. http://ncdrisc.org/.
Validation of a diabetic risk score
PLOS ONE | https://doi.org/10.1371/journal.pone.0218933 October 9, 2019 15 / 16
37. Marques-Vidal P, Rodondi N, Bochud M, Chiolero A, Pecoud A, Hayoz D, et al. Predictive accuracy of
original and recalibrated Framingham risk score in the Swiss population. Int J Cardiol. 2009; 133
(3):346–53. https://doi.org/10.1016/j.ijcard.2008.01.004 PMID: 18485502
38. American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabe-
tes-2018. Diabetes Care. 2018; 41(Suppl 1):S13–S27. https://doi.org/10.2337/dc18-S002 PMID:
29222373
39. McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabe-
tes prevalence and cardiovascular risk in South Asians. Lancet. 1991; 337(8738):382–6. https://doi.org/
10.1016/0140-6736(91)91164-p PMID: 1671422
40. Wijndaele K, Westgate K, Stephens SK, Blair SN, Bull FC, Chastin SF, et al. Utilization and Harmoniza-
tion of Adult Accelerometry Data: Review and Expert Consensus. Med Sci Sports Exerc. 2015; 47
(10):2129–39. https://doi.org/10.1249/MSS.0000000000000661 PMID: 25785929
41. Dagenais GR, Gerstein HC, Zhang X, McQueen M, Lear S, Lopez-Jaramillo P, et al. Variations in Dia-
betes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban
and Rural Epidemiological Study. Diabetes Care. 2016; 39(5):780–7. https://doi.org/10.2337/dc15-
2338 PMID: 26965719
42. McNamara CL, Balaj M, Thomson KH, Eikemo TA, Solheim EF, Bambra C. The socioeconomic distri-
bution of non-communicable diseases in Europe: findings from the European Social Survey (2014) spe-
cial module on the social determinants of health. Eur J Public Health. 2017; 27(suppl_1):22–6. https://
doi.org/10.1093/eurpub/ckw222 PMID: 28355638
43. Gujral UP, Mohan V, Pradeepa R, Deepa M, Anjana RM, Narayan KM. Ethnic differences in the preva-
lence of diabetes in underweight and normal weight individuals: The CARRS and NHANES studies.
Diabetes Res Clin Pract. 2018; 146:34–40. https://doi.org/10.1016/j.diabres.2018.09.011 PMID:
30244052
44. Luo J, Hendryx M, Laddu D, Phillips LS, Chlebowski R, LeBlanc ES, et al. Racial and Ethnic Differences
in Anthropometric Measures as Risk Factors for Diabetes. Diabetes Care. 2019; 42(1):126–33. https://
doi.org/10.2337/dc18-1413 PMID: 30352893
Validation of a diabetic risk score
PLOS ONE | https://doi.org/10.1371/journal.pone.0218933 October 9, 2019 16 / 16
